{
    "eid": "2-s2.0-85139514859",
    "title": "An economic evaluation of knee osteoarthritis treatments in Thailand",
    "cover-date": "2022-09-26",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "cost-utility analysis",
        "economic evaluation",
        "etoricoxib",
        "glucosamine",
        "knee osteoarthritis"
    ],
    "authors": [
        "Parnnaphat Luksameesate",
        "Aree Tanavalee",
        "Suthira Taychakhoonavudh"
    ],
    "citedby-count": 2,
    "ref-count": 52,
    "ref-list": [
        "Costs of lifetime treatment of acute coronary syndrome at Ramathibodi Hospital",
        "Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective",
        "The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: A systematic review and economic evaluation",
        "Rehospitalizations, early revisions, infections, and hospital resource use in the first year after hip and knee arthroplasties",
        "The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial",
        "Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys",
        "Cost-effectiveness evaluation of glucosamine for osteoarthritis based on simulation of individual patient data obtained from aggregated data in published studies",
        "Comparison of simultaneous bilateral with unilateral total knee arthroplasty in terms of perioperative complications",
        "Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme: A randomised comparison",
        "Efficiency of naproxen/esomeprazole in association for osteoarthrosis treatment in Spain",
        "National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions--United States (2003)",
        "Cost-effectiveness analysis of glucosamine sulphate for the treatment of osteoarthritis in Thailand",
        "Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors",
        "Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies",
        "Outcomes of total hip and knee replacement: Preoperative functional status predicts outcomes at six months after surgery",
        "Cost-effectiveness analysis of intra-articular injections of a high molecular weight bioengineered hyaluronic acid for the treatment of osteoarthritis knee pain",
        "Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: A randomized, double\u2010blind, placebo\u2010controlled study using acetaminophen as a side comparator",
        "Readmissions after fast-track hip and knee arthroplasty",
        "Cost-effectiveness analysis of branded and authorized generic celecoxib for patients with chronic pain in Japan",
        "Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities",
        "Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis",
        "Value of information in the osteoarthritis setting: Cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors",
        "Cost-effectiveness analysis of celecoxib on an avoidance of gastrointestinal adverse events in patients with osteoarthritis",
        "Disease-modifying drugs for knee osteoarthritis: Can they be cost-effective?",
        "Health Technology assessment (HTA) evidence, regulatory classification and reimbursement of medicine: The case of glucosamine",
        "Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: A randomized clinical trial",
        "Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK",
        "Cardiovascular risk associated with NSAIDs and COX-2 inhibitors",
        "The impact of osteoarthritis in the United States: A population-health perspective: A population-based review of the fourth most common cause of hospitalization in US adults",
        "Cost-effectiveness analysis of highly concentrated n-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction",
        "Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis",
        "Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT",
        "Glucosamine sulphate in the treatment of knee osteoarthritis: Cost\u2010effectiveness comparison with paracetamol",
        "Minimizing complications from nonsteroidal antiinflammatory drugs: Cost\u2010effectiveness of competing strategies in varying risk groups",
        "Preference-based EQ-5D index scores for chronic conditions in the United States",
        "Economic evaluation of HMG-CoA reductase inhibitors (statin) for primary prevention of cardiovascular diseases among Thai population",
        "Coverage decisions and the court: A public health perspective on glucosamine reimbursement in Thailand",
        "Revisit roles of HTA on drug policy in universal health coverage in Thailand: Where are we? And what is next?",
        "Direct unit cost of total knee replacement in ChiangRai prachanukroh hospital",
        "Osteoarthritis",
        "Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan",
        "A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Ratchadaphiseksomphot Endowment Fund",
        "Chulalongkorn University"
    ]
}